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Aims: This study aimed to examine whether any significant differences existed in trial protocol compli-
ance in target volumes (TV) and organs at risk (OARs) contouring amongst clinical oncologists specialised
in lung cancer radiotherapy.
Materials/methods: Two lung radiotherapy trials that require all prospective investigators to submit pre-
trial outlining quality assurance (QA) benchmark cases were selected. The contours from the benchmark
cases were compared against a set of reference contours which were defined by the trial management
group (TMG). In order to quantify the degree of variation in TV and OARs contouring, the matching index
(MI), Dice coefficient (DICE), Jaccard index (JI), Van‘t Riet Index and geographical miss index (GMI) were
calculated.
Results: A total of 198 structures contoured by 21 clinicians were collected from the outlining benchmark
cases. There were 40 clinical target volumes (CTV), 32 spinal cord, 36 oesophagus, 36 heart and 54 lungs
volumes included in the study. Analysis of the pre-trial benchmark cases revealed statistically significant
differences (p  0.05) in trial protocol compliances between clinical oncologists’ target volume and
organs at risk contours. Our results demonstrated that the lung contours had the highest level of confor-
mity, followed by heart, CTV, spinal cord and oesophagus respectively.
Conclusions: This study showed that there was a statistically significant difference in trial protocol com-
pliance for lung clinical oncologists’ TV and OARs contouring within the pre-trial QA benchmark cases.
Trial protocol compliances of TV and OARs delineation can be identified through assessing outlining
QA benchmark cases.
Crown Copyright  2019 Published by Elsevier B.V. on behalf of European Society for Radiotherapy &
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Background
In the last decade, there have been progressive developments in
the technology used for planning and delivery of lung radiotherapy
(RT). Advanced RT techniques such as intensity modulated RT
(IMRT), volumetric arc therapy (VMAT) and image guided
radiotherapy (IGRT) facilitate a change from a ‘one-size-fits-all’
approach to more personalised radiation treatments [1,2]. Theconcept of isotoxic lung RT which allows the radiation dose pre-
scription to the tumour to be tailored based upon normal tissue
constraints was recently explored in the Isotoxic Dose Escalation
and Acceleration in Lung Cancer ChemoRadiotherapy (IDEAL-
CRT) and ISoToxic Accelerated RadioTherapy in locally advanced
non-small cell lung cancer (I-START) trials [3,4].
This individualised isotoxic treatment approach depends heav-
ily on a clinician’s own interpretation of radiological cross-
sectional anatomy and requires clinicians to differentiate between
‘normal’ and ‘abnormal’ body tissues. This makes the process of
both target volume (TV) and organs at risk (OAR) delineations
highly observer dependent and at significant risk of
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lished research has focused on the extent of inter-observer varia-
tion concerning the TV delineation, and much less work has been
conducted on inter-observer variability involving OAR [6–9].
Against this background, this study was carried out to quantify
the degree of variation in TV and OARs amongst clinical oncologists
participating in the IDEAR-CRT and I-START trials.
Materials and methods
IDEAL-CRT and I-START trials quality assurance (QA)
The IDEAL-CRT trial was a phase I/II multi-centre trial evaluat-
ing the toxicity, feasibility and potential clinical effectiveness of
isotoxic, dose-escalated RT with concurrent chemoradiotherapy
in patients with stage II or stage III non-small cell lung cancer
(NSCLC) [3]. The I-START trial was a phase II multi-centre trial eval-
uating the toxicity, feasibility and potential clinical effectiveness of
isotoxic, accelerated and dose-escalated RT sequential to
chemotherapy in patients with more locally advanced stage II to
stage IIIB NSCLC [4].
In the UK, the National Cancer Research Institute (NCRI) has
established the National Radiotherapy Trials QA group (RTTQA)
to co-ordinate clinical trial QA work. As part of the trial QA pro-
gramme for both the IDEAL-CRT and I-START trials, all participating
centres were asked to complete two outlining QA benchmark exer-
cise prior to site activation. The same outlining QA benchmark
exercises were utilised by both trials. The QA exercises were locally
advanced, stage III lung cancers with tumours located centrally
within the chest. Background case histories, diagnostic imaging
scans (PET-CT) with the reports were provided along with the plan-
ning CT scan. The QA instructions requested clinicians to create
structures including the clinical target volume (CTV), spinal cord,
oesophagus, heart and lungs.
Contouring variations in TV and OARs
All completed outlining QA benchmark cases were submitted to
the RTTQA group for review. These were first reviewed by the trial
QA team for trial protocol outlining compliance. The TV and OARsFig. 1. Displaying an example CT Slice from thcontours from each clinician’s QA exercise submission were com-
pared against a set of reference contours which was defined by
the trial management group (TMG) (Fig. 1). This QA approach,
whereby a TMG reference contour set is utilised, has already been
validated by the UK’s RTTQA group [10]. Once the trial QA team
had completed their review, a detailed feedback report was created
and sent back to the submitting clinician.
For this analysis, and to allow the quantification of the degree of
variation that exists amongst clinicians participating in the IDEAL-
CRT and iSTART trials, the TV and OAR contours from clinician’s
first submissions were collected from both QA benchmark cases
and analysed against the TMG reference contour set. In total, one
simple volume measurement index: matching index (MI) and four
common conformity indices (CI) including the Dice coefficient
(DICE), Jaccard index (JCI), Van‘t Riet Index (RIET) and geographical
miss index (GMI) were calculated to allow assessment of under
and over outlining. These indices were selected on the basis that
they offer useful variations in the assessment of clinician contours
[11–16]. MI compares two simple contours incorporating the dif-
ferences in volumes: 100% implies a perfect match between two
contours. In this analysis, 1-GMI was calculated and used instead
of GMI to permit the use of a single scale of conformity for all four
CI whereby 1.0 represented perfect contour conformity and 0 rep-
resented no conformity.
Analysis
For each CI, Kruskai-Wallis ANOVA was performed to detect
whether any statistically significant differences in trial protocol
compliances between TV and OAR, volumes existed. This was then
followed by a Bonferroni-type multiple comparison to establish the
hierarchy. A Bonferroni correction was utilised to counteract the
problem of multiple comparisons.
Results
A total 198 structures were contoured in 40 case submissions
and they were used in the analysis. There were 40 CTV, 32 spinal
cord, 36 oesophagus, 36 heart and 54 lungs (27 left and 27 right
lungs) volumes included in the analysis. As suggested in Fig. 2,e QA case with TMG Reference Contours.
Fig. 2. Displays the number of submissions per structure in the QA cases.
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were 32% of the QA cases without the lung volumes delineated.
Descriptive statistics were summarised for all indices of each
structure in Table 1. In terms of the CTV contouring, it showed
an excellent mean MI to the TMG reference contour set of
99.34%. The mean DICE and JCI values of CTV were 0.84 (95%CI
0.81 – 0.87) and 0.73 (95%CI 0.69–0.77) respectively. Reviewing
the standard deviations stated in Table 1, the highest variations
were found in spinal cord and oesophagus in all five indices. Statis-
tically significant differences in trial protocol compliances were
detected for all five indices when comparing between the struc-
tures. This warranted for the pairwise comparisons to establish
the hierarchy of trial protocol compliance of each structure.Table 1
Summarises the descriptive statistics of MI, DICE, JACCARD, RIET and 1-GMI for CTV, spin
Mean index value Standard deviation
MI CTV 99.34% 0.4%
Spinal Cord 97.16% 1.1%
Oesophagus 96.03% 0.6%
Heart 99.87% 0.1%
Lungs 99.95% 0.1%
DICE CTV 0.84 0.10
Spinal Cord 0.74 0.12
Oesophagus 0.64 0.13
Heart 0.92 0.04
Lungs 0.97 0.01
JCI CTV 0.73 0.13
Spinal Cord 0.60 0.14
Oesophagus 0.48 0.14
Heart 0.86 0.06
Lungs 0.95 0.02
RIET CTV 0.72 0.14
Spinal Cord 0.58 0.15
Oesophagus 0.44 0.15
Heart 0.85 0.06
Lungs 0.95 0.02
1-GMI CTV 0.86 0.12
Spinal Cord 0.82 0.17
Oesophagus 0.67 0.18
Heart 0.91 0.06
Lungs 0.96 0.03As Table 2 demonstrates, significant differences were found in
all Bonferroni-type multiple comparisons, apart from Heart vs
Lungs in DICE, and CTV vs Spinal Cord, CTV vs Heart and Heart vs
Lungs in 1-GMI.
The lung contours had the highest level of conformity to the
TMG reference contour set, followed by heart, CTV, spinal cord
and oesophagus in all indices.
Discussion
This study has examined whether any significant differences
exist in trial protocol compliance in specialist lung cancer clinical
oncologist’s TV and OARs contouring through the analysis of twoal cord, oesophagus, heart and lungs contours.
95% Confidence interval for mean Kruskai-Wallis ANOVA
Lower bound Upper bound
99.22% 99.45% P < 0.05
96.76% 97.57%
95.84% 96.22%
99.86% 99.88%
99.94% 99.96%
0.81 0.87 P < 0.05
0.69 0.78
0.60 0.69
0.91 0.93
0.97 0.98
0.69 0.77 P < 0.05
0.54 0.65
0.44 0.53
0.84 0.88
0.94 0.95
0.68 0.77 P < 0.05
0.52 0.63
0.39 0.49
0.83 0.87
0.94 0.95
0.82 0.90 P < 0.05
0.76 0.88
0.61 0.73
0.89 0.93
0.95 0.97
Table 2
Summaries the results of the Bonferroni-type multiple comparisons between contours for the MI, DICE,
JACCARD, RIET and 1-GMI. The cells with non-significant P values (>0.05) have been highlighted.
Comparisons MI DICE JCI RIET 1-GMI
CTV vs Spinal Cord P<0.05 P<0.05 P<0.05 P<0.05 P=1.00
CTV vs Oesophagus P<0.05 P<0.05 P<0.05 P<0.05 P<0.05
CTV vs Heart P<0.05 P<0.05 P<0.05 P<0.05 P=0.61
CTV vs Lungs P<0.05 P<0.05 P<0.05 P<0.05 P<0.05
Spinal Cord vs Oesophagus P<0.05 P<0.05 P<0.05 P<0.05 P<0.05
Spinal Cord vs Heart P<0.05 P<0.05 P<0.05 P<0.05 P<0.05
Spinal Cord vs Lungs P<0.05 P<0.05 P<0.05 P<0.05 P<0.05
Oesophagus vs Heart P<0.05 P<0.05 P<0.05 P<0.05 P<0.05
Oesophagus vs Lungs P<0.05 P<0.05 P<0.05 P<0.05 P<0.05
Heart vs Lungs P=1.00 P=0.08 P<0.05 P<0.05 P=0.57
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two UK national lung cancer trials, IDEAL-CRT and I-START. Our
study found that high concordances of TV and OARs to TMG refer-
ence contour set in these two lung cancer trials. There were statis-
tically significant differences in trial protocol compliance in TV and
each OAR contouring for both volume measurement index and CIs
analysed. It suggested that lung contours had the highest level of
conformity to the TMG reference contour set, followed by heart,
CTV, spinal cord and oesophagus for all four indices analysed.
As demonstrated in Table 1, the mean value of JCI for the CTV
was 0.73 (CI 0.69–0.77). This was comparable to the findings
reported by Grills et al. and Konert et al. [17,18]. The reason of
selecting CTV instead of gross tumour volume (GTV) for QA analy-
sis in this study is to take account of the delineation accuracy of
how well the clinicians revised the CTV according to surrounding
anatomical boundaries after growing it from the GTV.
When defining the target volume, clinicians often try to avoid
missing out macroscopic tumour or areas considered to be at risk
of harbouring microscopic disease from their volume. Hence, it
would seem more likely that clinicians tend to over outline rather
than under outline their target volumes [6]. This concept might
explain why the CTV had such low levels of under outlining when
assessed using the DICE (mean value 0.84) and 1-GMI (mean value
0.86). Assessment of the RIET for the target group (mean value
0.72) was lower than that of the DICE supporting this theory.
Several studies have shown the benefits of the addition of com-
plimentary imaging modalities in improving TV delineation accu-
racy [7,9,17,18]. The outlining QA benchmark exercise included
background case histories and diagnostic PET-CT imaging scans
with reports to aid the clinicians with their TV delineation. How-
ever, such detailed guidance was not implemented to aid clinicians
in their OAR contouring. This could be explained on the basis that
the target volume contains the tumour and is therefore deemed by
the clinician to be the most important volume to be defined. This is
supported by Fig. 1 indicating that there was a 100% submission
rate of CTV volumes and only 68% of the QA cases were with lung
volumes submitted.
Sub-optimal TV definition negatively impacts on the chances of
cancer cure. Hence it is therefore likely for clinicians to put more
focus on implementing different contouring strategies to improve
the accuracy of TV delineation.
As illustrated in Table 1, the lungs had the highest levels of con-
formity whilst the oesophagus had the lowest in the context of the
IDEAL and I-START trials QA. The excellent conformity in the lungs’
contour could be explained by the fact that these were largelyauto-contoured as per the gold standard contours using the auto-
segmentation function of the radiotherapy treatment planning sys-
tem (TPS) with minimal clinician input. Therefore, the degree of
contouring variation witnessed would seem to be dramatically
minimised when the human interaction is largely removed from
the delineation process. In line with the published data by La Mac-
chia et al., our findings (as shown in the standard deviations of
Table 1) validate the ability of the auto-segmentation algorithm
to accurately outline normal lung contours [19]. Besides, it is noted
that the lung volumes are generally much larger in comparison to
OARs such as spinal cord and oesophagus. This may cause a higher
chance of geometrically overlap in lungs contour, resulting in high
conformity to TMG reference set and low variations between cases.
Regarding the oesophagus, the analysis on the indices sug-
gested that both under-outlining (not including the actual organ)
and over-outlining (including structures which are not the organ)
seemed to be present over the anatomical course of the organ.
Based on the oesophagus’ anatomical location and its proximity
to other central mediastinal structures, it can be difficult for clini-
cians to interpret the organ’s precise boundaries and anatomical
course. This is particularly problematic in studies of isotoxic dose
escalation where the dose to the oesophagus is a critical part of
the dose escalation algorithm. It is unclear what complementary
imaging techniques could address this problem.
The complex nature of advanced radiotherapy can introduce
uncertainty in the reproducibility and accuracy of treatment. This
may be amplified in a multi-centre clinical trial setting without a
comprehensive QA programme, especially when the advanced
radiotherapy techniques required are unfamiliar to participating
centres [20–22]. Our study has demonstrated the statistically sig-
nificant variation that exists in trial protocol compliances of TV
and OAR contouring during the pre-trial QA period for two UK lung
cancer radiotherapy trials and therefore highlights the importance
of performing outlining QA for the purposed of clinician feedback
to help minimise contouring variation. Misinterpretations of
per-protocol TV and OARs delineation can be identified through
assessing outlining QA benchmark cases and potential solutions
developed through discussion between the RTTQA team and
TMG. Such collaborations between the RTTQA team and TMG has
already been demonstrated to be an invaluable resource for
providing UK centres with a strong, cooperative network and safe
environment for implementing new advanced radiotherapy tech-
niques [10,20,21].
Recently it has been recommended by the Royal College of
Radiologists in the UK, that radiotherapy departments should have
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TV and OAR [23]. The QA benchmark exercises in this study can
be utilised as a common test case for departments to include in
their own annual audit programme. Our analysis on TV and OAR
contouring in two UK lung radiotherapy trials provide valuable
insight on the current standard for clinical oncologists contouring
and permits the ability for clinicians and radiotherapy depart-
ments to be benchmarked against each other.
It is acknowledged that the main limitation of our study is that
the results only represent a snapshot of UK lung cancer focused
clinical oncologists’ contouring conformity during the pre-accrual
trial QA benchmark period. In order to ensure that the level of con-
sistency in TV and OARs contouring is maintained, it is suggested
that all participating clinicians should repeat the benchmark QA
case exercise at pre-defined time points whilst the trial remains
open to recruitment i.e. every 12 months. Analysis of these subse-
quent benchmark cases could be used to detect whether inter-
observer variation in TV and OAR contouring deteriorates beyond
the completion of the initial pre-trial benchmark period.
Conclusion
Our findings suggest that high concordances of TV and OARs to
TMG reference contour set were found in the pre-trial QA of IDEAL-
CRT and I-START. There are statistically significant differences in
trial protocol compliances of TV and OAR contours produced by
specialists within the pre-trial QA benchmark cases. With the
introduction of an individualised isotoxic RT approach in a clinical
trial, it is important to ensure that both TV and OARs are contoured
consistently and accurately according to a comprehensive and
clearly defined trial protocol because inter-observer variation in
OAR delineation could have a significant impact on both the final
prescription dose and the dose received by the contoured OAR
within the isotoxic radiotherapy setting.
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